Clinical trials and real-world evidence show that, in addition to lowering HbA1c levels, GLP-1 agonists significantly reduce BMI, one of the primary therapeutic targets in obese patients with T2DM [12,13]. Here, GLP1R is linked to type 2 diabetes mellitus.